Intravenous (IV) infusion systems provider Fluidnet has appointed Benjamin Bulkley as president and chief executive officer, effective immediately. He will succeed the company's founder Jeffrey Carlisle, who will serve as chief innovation officer.
Bulkley was most recently the chief operating officer of Allscripts, a provider of software, services, and connectivity solutions for healthcare providers and previously led the global commercial operations of Invitrogen, an innovator of biological tools for life science research.
Bulkley had joined Invitrogen after 16 years with the General Electric Company in a variety of leadership roles in the healthcare, energy and transportation fields, ultimately leading the global service business for GE’s healthcare IT division.
Bulkley has began his career in systems engineering and program management roles innovating high reliability, low cost solutions in the transportation industry.
Fluidnet chairman Chuck Hadley said that Fluidnet is fortunate to have Ben to lead the company through FDA clearance of its innovative infusion delivery system and drive the growth of the business.
The Fluidnet system, once cleared, will offer a transformational change in performance and its architecture includes advanced fluidics, consumer electronics, and software development methods.